Tags

Type your tag names separated by a space and hit enter

In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection.
Drugs R D. 2020 May 06 [Online ahead of print]DR

Abstract

BACKGROUND

Clostridium difficile infection is the leading cause of hospital-acquired gastrointestinal infection and incidence rates continue to rise. Clostridium difficile infection is becoming increasingly complex to treat owing to the rise in treatment failures and recurrent infections. There is a clear need for new therapeutic options for the management of this disease.

OBJECTIVE

This study aimed to assess auranofin, a drug approved for the treatment of arthritis, as a treatment for C. difficile infection. Previous investigations have demonstrated potential antimicrobial activity of auranofin against C. difficile and other organisms.

METHODS

The activity of auranofin was assessed by in vitro investigations of its effect on C. difficile M7404 growth, vegetative cell viability, and spore viability. Activity of auranofin was also compared to that of the current treatments, metronidazole and vancomycin.

RESULTS

Auranofin showed bactericidal activity at concentrations as low as 4.07 µg/mL, effectively reducing bacterial cell density by 50-70% and the viable vegetative cell and spore yields by 100%. The activity of auranofin was shown to be non-inferior to that of metronidazole and vancomycin.

CONCLUSIONS

Auranofin is highly efficacious against C. difficile M7404 in vitro and has the potential to be an ideal therapeutic option for the treatment of C. difficile infection.

Authors+Show Affiliations

School of Medicine, Deakin University, Geelong, VIC, Australia. c.roder@deakin.edu.au. Department of Infectious Diseases, Barwon Health, Geelong, VIC, Australia. c.roder@deakin.edu.au.School of Medicine, Deakin University, Geelong, VIC, Australia. Department of Infectious Diseases, Barwon Health, Geelong, VIC, Australia.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32377889

Citation

Roder, Christine, and Eugene Athan. "In Vitro Investigation of Auranofin as a Treatment for Clostridium Difficile Infection." Drugs in R&D, 2020.
Roder C, Athan E. In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection. Drugs R D. 2020.
Roder, C., & Athan, E. (2020). In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection. Drugs in R&D. https://doi.org/10.1007/s40268-020-00306-3
Roder C, Athan E. In Vitro Investigation of Auranofin as a Treatment for Clostridium Difficile Infection. Drugs R D. 2020 May 6; PubMed PMID: 32377889.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection. AU - Roder,Christine, AU - Athan,Eugene, Y1 - 2020/05/06/ PY - 2020/5/8/entrez JF - Drugs in R&D JO - Drugs R D N2 - BACKGROUND: Clostridium difficile infection is the leading cause of hospital-acquired gastrointestinal infection and incidence rates continue to rise. Clostridium difficile infection is becoming increasingly complex to treat owing to the rise in treatment failures and recurrent infections. There is a clear need for new therapeutic options for the management of this disease. OBJECTIVE: This study aimed to assess auranofin, a drug approved for the treatment of arthritis, as a treatment for C. difficile infection. Previous investigations have demonstrated potential antimicrobial activity of auranofin against C. difficile and other organisms. METHODS: The activity of auranofin was assessed by in vitro investigations of its effect on C. difficile M7404 growth, vegetative cell viability, and spore viability. Activity of auranofin was also compared to that of the current treatments, metronidazole and vancomycin. RESULTS: Auranofin showed bactericidal activity at concentrations as low as 4.07 µg/mL, effectively reducing bacterial cell density by 50-70% and the viable vegetative cell and spore yields by 100%. The activity of auranofin was shown to be non-inferior to that of metronidazole and vancomycin. CONCLUSIONS: Auranofin is highly efficacious against C. difficile M7404 in vitro and has the potential to be an ideal therapeutic option for the treatment of C. difficile infection. SN - 1179-6901 UR - https://www.unboundmedicine.com/medline/citation/32377889/In_Vitro_Investigation_of_Auranofin_as_a_Treatment_for_Clostridium_difficile_Infection L2 - https://dx.doi.org/10.1007/s40268-020-00306-3 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.